Eli Lilly and Company (BKK:LLY80)
Thailand · Delayed Price · Currency is THB | Market Cap | 30.99T +39.7% |
| Revenue (ttm) | 2.36T +47.4% |
| Net Income | 824.94B +127.6% |
| EPS | 918.74 +129.1% |
| Shares Out | n/a |
| PE Ratio | 37.56 |
| Forward PE | 28.69 |
| Dividend | 0.01 (0.50%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 2,920,247 |
| Open | 1.750 |
| Previous Close | 1.770 |
| Day's Range | 1.740 - 1.780 |
| 52-Week Range | 1.010 - 1.830 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 30, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
The deals are part of Eli Lilly's effort to expand into infectious disease research and development. Shares edged higher in premarket trading on the news.
Eli Lilly agrees to acquire Curevo, LimmaTech Biologics, Vaccine Company
Eli Lilly (LLY) and Company announced agreements to acquire three companies, Curevo, LimmaTech Biologics, and Vaccine Company, that expand its research and development efforts into infectious disease....
Eli Lilly agrees to acquire Curevo for up to $1.5B in cash
Curevo’s lead product candidate is amezosvatein, an adjuvanted subunit vaccine for the prevention of shingles in adults. While the current standard of care for shingles prevention is effective, tolera...
Eli Lilly agrees to acquire LimmaTech Biologics for up to $780M in cash
LimmaTech Biologics is developing vaccines against bacterial pathogens for which rising antimicrobial resistance is steadily closing therapeutic options, including Staphylococcus aureus, Neisseria gon...
Eli Lilly agrees to acquire Vaccine Company for up to $1.55B in cash
Vaccine Company is developing proprietary In Vivo Nanoparticle technologies designed to enable the antigen display known to elicit durable immune responses associated with virus-like particle vaccines...
Lilly announces three acquisitions to build infectious disease portfolio
Agreements with Curevo, LimmaTech Biologics and Vaccine Company address viral pathogens linked to long-term neurological and oncological risk, and bacterial pathogens that are difficult to prevent or ...
Eli Lilly agrees to buy vaccine makers in deals worth up to $4B, WSJ reports
Eli Lilly (LLY) is expanding into infectious-disease prevention through acquisitions of vaccine developers Curevo, LimmaTech Biologics, and Vaccine Co. in deals worth up to nearly $4B combined, adding...
Lilly Agrees to Buys Trio of Vaccine Developers
The weight-loss drug market leader is renewing a focus on infectious-disease prevention.
Lilly Agrees to Buy Trio of Vaccine Developers
The weight-loss drug market leader is renewing a focus on infectious-disease prevention.
Eli Lilly announces Phase 1b Heart-2 study results for Verve-102
Eli Lilly (LLY) and Company announced positive Phase 1b Heart-2 study results for Verve-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in…
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
In the Phase 1b Heart-2 trial, a single intravenous infusion of VERVE-102 produced dose-dependent lowering of PCSK9 and LDL-C, with both reductions sustained over follow-up of up to 18 months in parti...
Studies suggest Ozempic, Mounjaro may slow tumor progression, WSJ reports
New studies suggest GLP-1 drugs such as Ozempic and Mounjaro, developed by Novo Nordisk (NVO) and Eli Lilly (LLY), may significantly improve cancer outcomes by reducing tumor progression, lowering mor...
Eli Lilly’s (LLY) Next-Generation Weight-Loss Drug Clears Big Hurdle
The company has a growing number of obesity medications.
Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
Phase 3 LIBRETTO-432 study evaluating Retevmo (selpercatinib) as adjuvant therapy in RET fusion-positive NSCLC to be featured in the Plenary Session and ASCO press program Investigator-initiated study...
LLY Clears Major Obesity Trial: Get Exposure in THNR
Weight loss drugs have been a big growth area in pharmaceuticals since GLP-1s hit the scene. This booming market has also breathed new life into companies like Eli Lilly (LLY), turning the stock into ...
How High Can Eli Lilly’s Stock (LLY) Price Go?
Eli Lilly stock still has major upside potential, according to one top analyst.
Eli Lilly's New GLP-1 Drug Looks Like a Weight-Loss Powerhouse in New Trial
Eli Lilly's investigational drug, retatrutide, delivered an average 80-week weight loss of 70 pounds at the highest dose.
Eli Lilly’s retatrutide readout strengthens long-term narrative, says Truist
Truist keeps the firm’s Buy rating and a $1,281 price target on Eli Lilly (LLY). The company’s retatrutide Phase 3 clinical trial data in obesity announced this morning, where patients…
Eli Lilly ‘sets new bar’ with retatrutide trial results, says Wolfe Research
Eli Lilly (LLY) reported pivotal phase 3 results for retatrutide showing class-leading weight loss of up to 26.1% at 80 weeks and over 30% at 104 weeks in higher-BMI participants,…
Eli Lilly’s retatrutide Triumph-1 study a ‘clean win’, says RBC Capital
RBC Capital keeps the firm’s Outperform rating and a $1,250 price target on Eli Lilly (LLY). The company’s retatrutide Phase 3 clinical trial showing that the drug meets the primary…
Lilly's new experimental shot produced 28% weight loss
The injection is different than Zepbound and Foundayo. It includes GIP, GLP-1, and glucagon
Eli Lilly's New Weight-Loss Treatment Shows Promising Results
An investigational drug developed by Eli Lilly delivered clinically meaningful weight loss in a trial, the company said as it looks expand its obesity treatment portfolio amid soaring demand.
Eli Lilly reports retatrutide meets primary endpoint in TRIUMPH-1 study
Eli Lilly (LLY) announced topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational GIP, GLP-1, and glucagon triple hormone recepto...
Patients on Lilly's next-gen obesity drug lost 28% of body weight, company says
Eli Lilly said on Thursday that its experimental drug retatrutide helped patients diagnosed with obesity lose more than 28% of their weight over a year and a half in a key trial that helps pave the w...
Eli Lilly says next-generation weight loss drug clears crucial obesity trial
Eli Lilly said its next-generation drug cleared a crucial late-stage trial in patients with obesity, delivering significant weight loss across doses. The results bring Lilly one step closer to filing...